As­traZeneca ends dai­ly GLP-1/glucagon tri­als in switch to week­ly in­jec­tion op­tion for NASH, oth­er in­di­ca­tions

As­traZeneca is end­ing clin­i­cal tri­als of a dai­ly GLP-1/glucagon co-ag­o­nist as the Big Phar­ma re­fo­cus­es its re­sources on a week­ly in­jec­tion that goes af­ter the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER